Drug Allergy

Drug Allergy Guidelines (ACAAI/AAAAI)

Drug Allergy GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/88057

Contents of this Issue

Navigation

Page 25 of 25

Grading System for Recommendations Category/Grade Definition Strength of Recommendation A B C D E Directly based on category I evidence Directly based on category II evidence or extrapolated from category I evidence Directly based on category III evidence or extrapolated from category I or II evidence Directly based on category IV evidence or extrapolated from category I, II, or III evidence Based on consensus of the Joint Task Force on Practice Parameters Abbreviations ACE, angiotensin-converting enzyme; ADR, adverse drug reaction; AERD, aspirin-exacerbated respiratory disease; ARB, angiotensin receptor blocker; COX, cyclooxygenase; DILE, drug-induced lupus erythematosus; DMARDs, disease-modifying antirheumatic drugs; DRESS, drug rash with eosinophilia and systemic symptoms; FEV1 forced expiratory volume in 1 second; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; IgE, immunoglobulin E; NSAIDs, nonsteroidal anti-inflammatory drugs; RCM, radiocontrast media; SJS, Stevens-Johnson syndrome; SLE, systemic lupus erythematosus; TEN, toxic epidermal necrolysis; TMP-SMX, trimethoprim-sulfamethoxazole; TNF, tumor necrosis factor; TRALI, transfusion-related acute lung injury , Source Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259-273. Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. DRU021210 5740 Executive Drive Suite 218 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2012 All rights reserved

Articles in this issue

Links on this page

Archives of this issue

view archives of Drug Allergy - Drug Allergy Guidelines (ACAAI/AAAAI)